Cero Therapeutics Holdings, Inc. Files S-1 Registration Statement

Ticker: CEROW · Form: S-1 · Filed: Apr 10, 2024 · CIK: 1870404

Sentiment: neutral

Topics: S-1, Registration Statement, Cero Therapeutics, Public Offering, Phoenix Biotech Acquisition Corp.

TL;DR

<b>Cero Therapeutics Holdings, Inc. files S-1 registration statement for delayed/continuous offering.</b>

AI Summary

CERO THERAPEUTICS HOLDINGS, INC. (CEROW) filed a IPO Registration (S-1) with the SEC on April 10, 2024. Cero Therapeutics Holdings, Inc. has filed an S-1 registration statement with the SEC. The company was formerly known as Phoenix Biotech Acquisition Corp. and changed its name on June 30, 2021. Cero Therapeutics is incorporated in Delaware and its principal executive offices are located in South San Francisco, CA. The filing indicates the company is a smaller reporting company and a non-accelerated filer. The registration statement is for an offering of securities to be made on a delayed or continuous basis pursuant to Rule 415.

Why It Matters

For investors and stakeholders tracking CERO THERAPEUTICS HOLDINGS, INC., this filing contains several important signals. This S-1 filing signals Cero Therapeutics' intent to offer securities to the public, potentially for funding future operations or growth initiatives. The company's previous identity as Phoenix Biotech Acquisition Corp. and its recent name change may indicate a strategic shift or rebranding effort.

Risk Assessment

Risk Level: low — CERO THERAPEUTICS HOLDINGS, INC. shows low risk based on this filing. The filing is an S-1 registration statement, which is a preliminary step for a public offering and does not contain detailed financial performance data or operational results that would indicate immediate risk.

Analyst Insight

Monitor future filings for details on the proposed offering, including the number of shares, pricing, and use of proceeds.

Key Numbers

Key Players & Entities

FAQ

When did CERO THERAPEUTICS HOLDINGS, INC. file this S-1?

CERO THERAPEUTICS HOLDINGS, INC. filed this IPO Registration (S-1) with the SEC on April 10, 2024.

What is a S-1 filing?

A S-1 is a registration statement for initial public offerings, containing the prospectus with business description, financials, and risk factors. This particular S-1 was filed by CERO THERAPEUTICS HOLDINGS, INC. (CEROW).

Where can I read the original S-1 filing from CERO THERAPEUTICS HOLDINGS, INC.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by CERO THERAPEUTICS HOLDINGS, INC..

What are the key takeaways from CERO THERAPEUTICS HOLDINGS, INC.'s S-1?

CERO THERAPEUTICS HOLDINGS, INC. filed this S-1 on April 10, 2024. Key takeaways: Cero Therapeutics Holdings, Inc. has filed an S-1 registration statement with the SEC.. The company was formerly known as Phoenix Biotech Acquisition Corp. and changed its name on June 30, 2021.. Cero Therapeutics is incorporated in Delaware and its principal executive offices are located in South San Francisco, CA..

Is CERO THERAPEUTICS HOLDINGS, INC. a risky investment based on this filing?

Based on this S-1, CERO THERAPEUTICS HOLDINGS, INC. presents a relatively low-risk profile. The filing is an S-1 registration statement, which is a preliminary step for a public offering and does not contain detailed financial performance data or operational results that would indicate immediate risk.

What should investors do after reading CERO THERAPEUTICS HOLDINGS, INC.'s S-1?

Monitor future filings for details on the proposed offering, including the number of shares, pricing, and use of proceeds. The overall sentiment from this filing is neutral.

How does CERO THERAPEUTICS HOLDINGS, INC. compare to its industry peers?

The filing is an S-1 registration statement, which is a standard document filed by companies intending to offer securities to the public. It provides information about the company's business, financial condition, and management.

Are there regulatory concerns for CERO THERAPEUTICS HOLDINGS, INC.?

The filing is made under the Securities Act of 1933, which governs the registration of securities offered to the public in the United States.

Industry Context

The filing is an S-1 registration statement, which is a standard document filed by companies intending to offer securities to the public. It provides information about the company's business, financial condition, and management.

Regulatory Implications

The filing is made under the Securities Act of 1933, which governs the registration of securities offered to the public in the United States.

What Investors Should Do

  1. Review the full S-1 filing for detailed information on the proposed securities offering.
  2. Track subsequent SEC filings for updates on the offering's progress and potential pricing.
  3. Research the company's business strategy and market position given its recent name change.

Year-Over-Year Comparison

This is the initial S-1 filing for Cero Therapeutics Holdings, Inc. under its current name, indicating a new phase for the company's public market activities.

Filing Stats: 4,627 words · 19 min read · ~15 pages · Grade level 16.2 · Accepted 2024-04-10 16:06:27

Key Financial Figures

Filing Documents

RISK FACTORS

RISK FACTORS 8 THE COMMITTED EQUITY FINANCINGS 67

USE OF PROCEEDS

USE OF PROCEEDS 74 DETERMINATION OF OFFERING PRICE 75 MARKET PRICE AND DIVIDEND INFORMATION 76 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION 77

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS OF PBAX

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS OF PBAX 124 MANAGEMENT OF CERO 130

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 140 DIRECTOR COMPENSATION 145 PRINCIPAL STOCKHOLDERS 146 SELLING SECURITYHOLDERS 149 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 151

DESCRIPTION OF SECURITIES

DESCRIPTION OF SECURITIES 153 SECURITIES ACT RESTRICTIONS ON RESALE OF OUR SECURITIES 164 PLAN OF DISTRIBUTION 165 LEGAL MATTERS 167 EXPERTS 167 WHERE YOU CAN FIND MORE INFORMATION 167 INDEX TO FINANCIAL STATEMENTS F -1 i ABOUT THIS PROSPECTUS This prospectus is part of a registration statement on Form S-1 that we filed with the SEC whereby the Selling Securityholders named herein may, from time to time, sell the securities offered by them described in this prospectus. We will not receive any proceeds from the sale by such Selling Securityholders of the securities offered by them described in this prospectus. Neither we nor the Selling Securityholders have authorized anyone to provide you with any information or to make any representations other than those contained in this prospectus or any applicable prospectus supplement or any free writing prospectuses prepared by or on behalf of us or to which we have referred you. Neither we nor the Selling Securityholders take responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. Neither we nor the Selling Securityholders will make an offer to sell these securities in any jurisdiction where such offer or sale is not permitted. No dealer, salesperson or other person is authorized to give any information or to represent anything not contained in this prospectus, any applicable prospectus supplement or any related free writing prospectus. You should assume that the information appearing in this prospectus or any prospectus supplement is accurate as of the date on the front of those documents only, regardless of the time of delivery of this prospectus or any applicable prospectus supplement, or any sale of a security. Our business, financial condition, results of operations and prospects may have changed since those dates. The Selling Securityholders and their permitted transferees may use this registration statement to sell se

View Full Filing

View this S-1 filing on SEC EDGAR

View on Read The Filing